Inhibition of SREBP activation, which simultaneously blocks all three key regulators of hepatic lipogenesis, SREBP, LXR, and ChREBP, has therapeutic potential for treatment of fatty liver disease (22). Here, MLXIPL is linked to fatty liver disease.